WO2024047394 - COMBINATION THERAPIES FOR TREATMENT OF T-CELL LYMPHOMAS WITH TOLINAPANT, CEDAZURIDINE AND DECITABINE
National phase entry is expected:
Publication Number
WO/2024/047394
Publication Date
07.03.2024
International Application No.
PCT/IB2022/060652
International Filing Date
04.11.2022
Title **
[English]
COMBINATION THERAPIES FOR TREATMENT OF T-CELL LYMPHOMAS WITH TOLINAPANT, CEDAZURIDINE AND DECITABINE
[French]
POLYTHÉRAPIES POUR LE TRAITEMENT DE LYMPHOMES À LYMPHOCYTES T AVEC TOLINAPANT, CÉDAZURIDINE ET DÉCITABINE
Applicants **
OTSUKA PHARMACEUTICAL CO., LTD.
2-9 Kanda Tsukasa-Machi
Chiyoda-Ku, Tokyo 101-8535, JP
Inventors
SIMS, Martin John
c/o Astex Therapeutics Limited
436 Cambridge Science Park, Milton Road
Cambridge Cambridgeshire CB4 0QA, GB
WARD, George Albert
c/o Astex Therapeutics Limited
436 Cambridge Science Park, Milton Road
Cambridge Cambridgeshire CB4 0QA, GB
KEER, Harold
c/o Astex Pharmaceuticals, Inc.
4420 Rosewood Drive, Suite 200
Pleasanton, California 94588, US
OGANESIAN, Aram
c/o Astex Pharmaceuticals, Inc.
4420 Rosewood Drive, Suite 200
Pleasanton, California 94588, US
Priority Data
63/374,137
31.08.2022
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| * | |
International Searching Authority |
EPO
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Translation |
|
Recalculate
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing | 2302 | |
| EPO | Filing, Examination | 20553 | |
| Japan | Filing | 589 | |
| South Korea | Filing | 575 | |
| USA | Filing, Examination | 10235 |
Total: 34254 USD
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Abstract[English]
The present disclosure relates generally to methods of treating T-cell lymphomas with combination therapies.[French]
La présente divulgation concerne de manière générale des méthodes de traitement de lymphomes à lymphocytes T avec des polythérapies.